Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for NovaBay Pharmaceuticals (NBY) over the last 11 years, with Q3 2025 value amounting to $87000.0.

  • NovaBay Pharmaceuticals' Other Operating Expenses changed N/A to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year increase of 10966.67%. This contributed to the annual value of -$865000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Other Operating Expenses is $87000.0.
  • In the past 5 years, NovaBay Pharmaceuticals' Other Operating Expenses registered a high of $8.7 million during Q4 2022, and its lowest value of -$900000.0 during Q1 2024.
  • Over the past 4 years, NovaBay Pharmaceuticals' median Other Operating Expenses value was $1.9 million (recorded in 2022), while the average stood at $2.1 million.
  • Within the past 5 years, the most significant YoY rise in NovaBay Pharmaceuticals' Other Operating Expenses was 30330.08% (2022), while the steepest drop was 1096.56% (2022).
  • Over the past 4 years, NovaBay Pharmaceuticals' Other Operating Expenses (Quarter) stood at $2.2 million in 2021, then skyrocketed by 303.3% to $8.7 million in 2022, then crashed by 110.37% to -$900000.0 in 2024, then surged by 109.67% to $87000.0 in 2025.
  • Its last three reported values are $87000.0 in Q3 2025, -$900000.0 for Q1 2024, and $8.7 million during Q4 2022.